Panbela Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Panbela Therapeutics

03/05/2023 03:03

* Panbela Therapeutics Inc  PBLA.OQ   PBLA.O  is expected
to show
no change in quarterly revenue when it reports  results on May
4. 
    * 
    * ​Refinitiv's mean analyst estimate for Panbela
Therapeutics Inc
is for a loss of 54 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Panbela
Therapeutics Inc is $7​, above​ its last closing price of $0.45.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -3.81       -3.70      -5.68     Missed  -53.3
 Sep. 30 2022              -8.80      -8.40     Beat    4.5
 Jun. 30 2022  -10.12      -10.13     -60.40    Missed  -496.1
                                                        ​
 Mar. 31 2022  -10.16      -10.20     -10.80    Missed  -5.9
 ​​Dec.        -7.60       -7.20      -10.40    Missed  -44.4
 31 2021                                                
 Sep. 30 2021              -9.20      -6.40     Beat    30.4​
 Jun. 30 2021  -8.67       -7.07      -8.80     Missed  -24.5
 Mar. 31 2021  -4.40       -4.40      -9.20     Missed  -109.1
 This summary was machine generated May 3 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated